Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
Background: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses. Materials and Met...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-04-01
|
Series: | Indian Journal of Psychiatry |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832593599203639296 |
---|---|
author | Ramandeep Kaur Ajeet Sidana Nidhi Malhotra Shikha Tyagi |
author_facet | Ramandeep Kaur Ajeet Sidana Nidhi Malhotra Shikha Tyagi |
author_sort | Ramandeep Kaur |
collection | DOAJ |
description | Background:
There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses.
Materials and Methods:
Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks.
Results:
Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group.
Conclusion:
LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL. |
format | Article |
id | doaj-art-23f063b49b5a44cbbc2a21d5b75117ba |
institution | Kabale University |
issn | 0019-5545 1998-3794 |
language | English |
publishDate | 2023-04-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Indian Journal of Psychiatry |
spelling | doaj-art-23f063b49b5a44cbbc2a21d5b75117ba2025-01-20T11:14:26ZengWolters Kluwer Medknow PublicationsIndian Journal of Psychiatry0019-55451998-37942023-04-0165440441110.4103/indianjpsychiatry.indianjpsychiatry_389_22Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional studyRamandeep KaurAjeet SidanaNidhi MalhotraShikha TyagiBackground: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses. Materials and Methods: Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks. Results: Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group. Conclusion: LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL.https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22adherenceantipsychoticfesfirst-episode schizophrenialaiquality of life |
spellingShingle | Ramandeep Kaur Ajeet Sidana Nidhi Malhotra Shikha Tyagi Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study Indian Journal of Psychiatry adherence antipsychotic fes first-episode schizophrenia lai quality of life |
title | Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study |
title_full | Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study |
title_fullStr | Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study |
title_full_unstemmed | Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study |
title_short | Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study |
title_sort | oral versus long acting injectable antipsychotic in first episode schizophrenia a 12 weeks interventional study |
topic | adherence antipsychotic fes first-episode schizophrenia lai quality of life |
url | https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_389_22 |
work_keys_str_mv | AT ramandeepkaur oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy AT ajeetsidana oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy AT nidhimalhotra oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy AT shikhatyagi oralversuslongactinginjectableantipsychoticinfirstepisodeschizophreniaa12weeksinterventionalstudy |